Correlation of response with overall survival (OS) for nivolumab vs everolimus in advanced renal cell carcinoma (aRCC): Results from the phase III CheckMate 025 study Meeting Abstract
| Authors: | Motzer, R. J.; Sharma, P.; Escudier, B. J.; McDermott, D. F.; George, S.; Srinivas, S.; Tykodi, S. S.; Sosman, J. A.; Plimack, E. R.; Nathan, P. D.; Gruenwald, V.; Tomita, Y.; Zhao, H.; Waxman, I. M.; Hammers, H. J. |
| Abstract Title: | Correlation of response with overall survival (OS) for nivolumab vs everolimus in advanced renal cell carcinoma (aRCC): Results from the phase III CheckMate 025 study |
| Meeting Title: | 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 34 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2016 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-05-20 |
| Start Page: | 257s |
| Language: | English |
| ACCESSION: | WOS:000404665407125 |
| DOI: | 10.1200/JCO.2016.34.15_suppl.4552 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract : 4552 -- Source: Wos |
